Hill, C. et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014).
Liu, H. et al. A multicellular self-organized probiotic platform for oral delivery enhances intestinal colonization. Nat. Commun. 16, 7060 (2025).
Konstantinov, S. R. et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl Acad. Sci. USA 105, 19474–19479 (2008).
Asare, P. T. et al. Reuterin demonstrates potent antimicrobial activity against a broad panel of human and poultry meat Campylobacter spp. isolates. Microorganisms 8, 78 (2020).
Rutter, J. W. et al. A bacteriocin expression platform for targeting pathogenic bacterial species. Nat. Commun. 15, 6332 (2024).
Kamada, N. et al. Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect. Immun. 76, 214–220 (2008).
Baralić, K., Živančević, K., Bozic, D. & Đukić-Ćosić, D. Probiotic cultures as a potential protective strategy against the toxicity of environmentally relevant chemicals: state-of-the-art knowledge. Food Chem. Toxicol. 172, 113582 (2023).
O’Toole, P. W., Marchesi, J. R. & Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2, 17057 (2017).
Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. Nat. Med. 25, 716–729 (2019).
Baião, R. et al. Multispecies probiotic administration reduces emotional salience and improves mood in subjects with moderate depression: a randomised, double-blind, placebo-controlled study. Psychol. Med. 53, 3437–3447 (2023).
Asghari, K. M. et al. The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial. Sci. Rep. 13, 18577 (2023).
Gibson, G. R. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502 (2017).
Hutkins, R. et al. Classifying compounds as prebiotics — scientific perspectives and recommendations. Nat. Rev. Gastroenterol. Hepatol. 22, 54–70 (2025).
Swanson, K. S. et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 17, 687–701 (2020).
Lewis, Z. T. et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr. Res. 79, 445–452 (2016).
MarketsandMarkets. Probiotics Market Report (Global Forecast to 2029) (MarketsandMarkets, 2025).
McFarland, L. V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 16, 2202–2222 (2010).
Li, M. et al. Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery. Biomaterials 309, 122584 (2024).
Allegretti, J. R. et al. Safety and efficacy of fecal microbiota, live-jslm (REBYOTA®), for the prevention of recurrent Clostridioides difficile infection in participants with inflammatory bowel disease in PUNCH CD3-OLS. Inflamm. Bowel Dis. 31, 2112–2122 (2025).
Rosenberg, J. & Ritter, T. Practical use of fecal microbiota spores, live-brpk (formerly SER-109): an oral therapeutic for the prevention of recurrent Clostridioides difficile infection. Expert Rev. Antiinfect. Ther. 21, 687–690 (2023).
Feuerstadt, P. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N. Engl. J. Med. 386, 220–229 (2022).
Khanna, S. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs 82, 1527–1538 (2022).
Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822–834 (2020).
Rashidi, A. et al. Randomized double-blind phase II trial of fecal microbiota transplantation versus placebo in allogeneic hematopoietic cell transplantation and AML. J. Clin. Oncol. 41, 5306–5319 (2023).
Veiga, P., Suez, J., Derrien, M. & Elinav, E. Moving from probiotics to precision probiotics. Nat. Microbiol. 5, 878–880 (2020).
Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e21 (2018).
Hernández Medina, R. et al. Machine learning and deep learning applications in microbiome research. ISME Commun. 2, 98 (2022).
Marcos-Zambrano, L. J. et al. Applications of machine learning in human microbiome studies: a review on feature selection, biomarker identification, disease prediction and treatment. Front. Microbiol. 12, 634511 (2021).
Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174–180 (2011).
Li, N. & Guo, X. The gut microbiota and host immunity synergistically orchestrate colonization resistance. Gut Microbes 18, 2611545 (2026).
Merenstein, D. J. et al. Is there evidence to support probiotic use for healthy people? Adv. Nutr. 15, 100265 (2024).
McFarland, L. V., Evans, C. T. & Goldstein, E. J. C. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front. Med. 5, 124 (2018).
Kochan, P. et al. Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient — is the time right to revise probiotic safety guidelines? Clin. Microbiol. Infect. 17, 1589–1592 (2011).
Land, M. H. et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115, 178–181 (2005).
Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e16 (2018).
Zhang, W. et al. Bacteroides fragilis protects against antibiotic-associated diarrhea in rats by modulating intestinal defenses. Front. Immunol. 9, 1040 (2018).
Kang, C.-H. et al. Pasteurized Akkermansia muciniphila HB05 (HB05P) improves muscle strength and function: a 12-week, randomized, double-blind, placebo-controlled clinical trial. Nutrients 16, 4037 (2024).
Zhang, H. et al. Akkermansia muciniphila ONE effectively ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. npj Sci. Food 8, 97 (2024).
Xiao, X. et al. Akkermansia muciniphila supplementation improves hyperlipidemia, cardiac function, and gut microbiota in high fat fed apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat. 175, 106906 (2024).
Blacher, E. et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572, 474–480 (2019).
Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339–1353.e21 (2016).
Cox, L. M. et al. Gut microbiome in progressive multiple sclerosis. Ann. Neurol. 89, 1195–1211 (2021).
Walter, J., Maldonado-Gómez, M. X. & Martínez, I. To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes. Curr. Opin. Biotechnol. 49, 129–139 (2018).
Shen, X. et al. Short-term probiotic supplementation affects the diversity, genetics, growth, and interactions of the native gut microbiome. iMeta 3, e253 (2024).
Maldonado-Gómez, M. X. et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20, 515–526 (2016).
Chávarri, M. et al. Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions. Int. J. Food Microbiol. 142, 185–189 (2010).
Cook, M. T., Tzortzis, G., Charalampopoulos, D. & Khutoryanskiy, V. V. Microencapsulation of probiotics for gastrointestinal delivery. J. Control. Release 162, 56–67 (2012).
Tremblay, A. et al. Total transit time and probiotic persistence in healthy adults: a pilot study. J. Neurogastroenterol. Motil. 29, 218–228 (2023).
Singhal, R. & Shah, Y. M. Oxygen battle in the gut: hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine. J. Biol. Chem. 295, 10493–10505 (2020).
Kiu, R. et al. Particular genomic and virulence traits associated with preterm infant-derived toxigenic Clostridium perfringens strains. Nat. Microbiol. 8, 1160–1175 (2023).
Baishya, J. et al. The impact of intraspecies and interspecies bacterial interactions on disease outcome. Pathogens 10, 96 (2021).
Holzapfel, W., Arini, A., Aeschbacher, M., Coppolecchia, R. & Pot, B. Enterococcus faecium SF68 as a model for efficacy and safety evaluation of pharmaceutical probiotics. Benef. Microbes 9, 375–388 (2018).
Montealegre, M. C., Singh, K. V. & Murray, B. E. Gastrointestinal tract colonization dynamics by different Enterococcus faecium clades. J. Infect. Dis. 213, 1914–1922 (2016).
Leendertse, M. et al. Enterococcal surface protein transiently aggravates Enterococcus faecium-induced urinary tract infection in mice. J. Infect. Dis. 200, 1162–1165 (2009).
Leavis, H. L., Willems, R. J. L., Top, J. & Bonten, M. J. M. High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J. Clin. Microbiol. 44, 1059–1064 (2006).
Torres, M. et al. Bacterial fitness for plant colonization is influenced by plant growth substrate. N. Phytol. 248, 3168–3190 (2025).
Han, S. et al. Probiotic gastrointestinal transit and colonization after oral administration: a long journey. Front. Cell. Infect. Microbiol. 11, 609722 (2021).
Sassone-Corsi, M. et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540, 280–283 (2016).
Osbelt, L. et al. Variations in microbiota composition of laboratory mice influence Citrobacter rodentium infection via variable short-chain fatty acid production. PLoS Pathog. 16, e1008448 (2020).
Strock, R. et al. Archaea produce peptidoglycan hydrolases that kill bacteria. PLoS Biol. 23, e3003235 (2025).
Alavi, S. et al. Interpersonal gut microbiome variation drives susceptibility and resistance to cholera infection. Cell 181, 1533–1546.e13 (2020).
Long, X. et al. Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Cell Metab. 37, 2342–2361.e9 (2025).
Wang, H. et al. Microbial metabolite deoxycholic acid controls Clostridium perfringens-induced chicken necrotic enteritis through attenuating inflammatory cyclooxygenase signaling. Sci. Rep. 9, 14541 (2019).
Scott, S. A., Fu, J. & Chang, P. V. Dopamine receptor D2 confers colonization resistance via microbial metabolites. Nature 628, 180–185 (2024).
Caballero-Flores, G., Pickard, J. M. & Núñez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat. Rev. Microbiol. 21, 347–360 (2023).
Djukovic, A. et al. Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae. Nat. Commun. 13, 5617 (2022).
Foley, M. H. et al. Differential modulation of post-antibiotic colonization resistance to Clostridioides difficile by two probiotic Lactobacillus strains. mBio 16, e0146825 (2025).
von Meijenfeldt, F. A. B., Hogeweg, P. & Dutilh, B. E. A social niche breadth score reveals niche range strategies of generalists and specialists. Nat. Ecol. Evol. 7, 768–781 (2023).
Bakkeren, E., Piskovsky, V., Lee, M. N. Y., Jahn, M. T. & Foster, K. R. Strain displacement in microbiomes via ecological competition. Nat. Microbiol. 10, 3122–3135 (2025).
Heilbronner, S., Krismer, B., Brötz-Oesterhelt, H. & Peschel, A. The microbiome-shaping roles of bacteriocins. Nat. Rev. Microbiol. 19, 726–739 (2021).
Tang, Q. et al. Current sampling methods for gut microbiota: a call for more precise devices. Front. Cell. Infect. Microbiol. 10, 151 (2020).
Zhang, P. Influence of foods and nutrition on the gut microbiome and implications for intestinal health. Int. J. Mol. Sci. 23, 9588 (2022).
Tompkins, T. A., Mainville, I. & Arcand, Y. The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract. Benef. Microbes 2, 295–303 (2011).
Fan, P. et al. Host genetic effects upon the early gut microbiota in a bovine model with graduated spectrum of genetic variation. ISME J. 14, 302–317 (2020).
Federici, S. et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185, 2879–2898.e24 (2022).
Zuo, T. et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 67, 634–643 (2018).
Shimizu, K. et al. Identification of genes essential for bile acid resistance in the probiotic Lacticaseibacillus paracasei strain Shirota. Lett. Appl. Microbiol. 76, ovad062 (2023).
Mays, Z. J. S., Chappell, T. C. & Nair, N. U. Quantifying and engineering mucus adhesion of probiotics. ACS Synth. Biol. 9, 356–367 (2020).
Khan, M. T. et al. Synergy and oxygen adaptation for development of next-generation probiotics. Nature 620, 381–385 (2023).
Burrows, K. et al. A gut commensal protozoan determines respiratory disease outcomes by shaping pulmonary immunity. Cell 188, 316–330.e12 (2025).
Kruger, K. et al. Evaluation of inter- and intra-variability in gut health markers in healthy adults using an optimised faecal sampling and processing method. Sci. Rep. 14, 24580 (2024).
Rothwell, P. M. External validity of randomised controlled trials: ‘to whom do the results of this trial apply?’. Lancet 365, 82–93 (2005).
Chuang, Y.-F. et al. Precision probiotics supplement strategy in aging population based on gut microbiome composition. Brief. Bioinform. 25, bbae351 (2024).
Latif, A. et al. Probiotics: mechanism of action, health benefits and their application in food industries. Front. Microbiol. 14, 1216674 (2023).
Khailova, L. et al. Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS ONE 9, e97861 (2014).
Spacova, I. et al. Lactobacillus rhamnosus probiotic prevents airway function deterioration and promotes gut microbiome resilience in a murine asthma model. Gut Microbes 11, 1729–1744 (2020).
Walocha, R., Kim, M., Wong-Ng, J., Gobaa, S. & Sauvonnet, N. Organoids and organ-on-chip technology for investigating host–microorganism interactions. Microbes Infect. 26, 105319 (2024).
Yata, V. K. Ex vivo and miniaturized in vitro models to study microbiota–gut–brain axis. 3 Biotech 14, 280 (2024).
Krautkramer, K. A., Fan, J. & Bäckhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19, 77–94 (2021).
Mousa, W. K., Chehadeh, F. & Husband, S. Recent advances in understanding the structure and function of the human microbiome. Front. Microbiol. 13, 825338 (2022).
Ebigbo, N. et al. Optimizing precision probiotics for mitigating graft-versus-host disease. Microorganisms 13, 706 (2025).
Sanam, M. et al. Bridging two worlds: host microbiota crosstalk in health and dysregulation. Innate Immun. 31, 17534259251392993 (2025).
Garcia-Vello, P. et al. The lipooligosaccharide of the gut symbiont Akkermansia muciniphila exhibits a remarkable structure and TLR signaling capacity. Nat. Commun. 15, 8411 (2024).
Zhu, J. et al. Efficacy and safety of Lactobacillus acidophilus LA85 in preventing antibiotic-associated diarrhea: a randomized, placebo-controlled study. Food Sci. Nutr. 13, e70490 (2025).
García, G. et al. Randomized clinical trials demonstrate the safety assessment of Alkalihalobacillus clausii AO1125 for use as a probiotic in humans. Microorganisms 12, 2299 (2024).
Quin, C. et al. Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison. Sci. Rep. 8, 8283 (2018).
Mugambi, M. N., Musekiwa, A., Lombard, M., Young, T. & Blaauw, R. Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review. BMC Med. Res. Methodol. 13, 137 (2013).
Rijkers, G. T. et al. Health benefits and health claims of probiotics: bridging science and marketing. Br. J. Nutr. 106, 1291–1296 (2011).
Lerner, A., Benzvi, C. & Vojdani, A. The potential harmful effects of genetically engineered microorganisms (GEMs) on the intestinal microbiome and public health. Microorganisms 12, 238 (2024).
Boyle, R. J. et al. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin. Exp. Allergy 38, 1882–1890 (2008).
Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C. & Miller, L. E. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am. J. Gastroenterol. 105, 1636–1641 (2010).
Mohan, R. et al. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr. Res. 64, 418–422 (2008).
Olivares, M., Castillejo, G., Varea, V. & Sanz, Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br. J. Nutr. 112, 30–40 (2014).
Pellino, G. et al. Early postoperative administration of probiotics versus placebo in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial. BMC Surg. 13, S57 (2013).
Yang, Y. et al. Within-host evolution of a gut pathobiont facilitates liver translocation. Nature 607, 563–570 (2022).
Montassier, E. et al. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner. Nat. Microbiol. 6, 1043–1054 (2021).
Mukhopadhya, I. et al. Sporulation capability and amylosome conservation among diverse human colonic and rumen isolates of the keystone starch-degrader Ruminococcus bromii. Environ. Microbiol. 20, 324–336 (2018).
Uemura, K. et al. Rapid and integrated bacterial evolution analysis unveils gene mutations and clinical risk of Klebsiella pneumoniae. Nat. Commun. 16, 2917 (2025).
Martin, F.-P. J. et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol. Syst. Biol. 4, 157 (2008).
Rottinghaus, A. G., Ferreiro, A., Fishbein, S. R. S., Dantas, G. & Moon, T. S. Genetically stable CRISPR-based kill switches for engineered microbes. Nat. Commun. 13, 672 (2022).
George, D. R. et al. A bumpy road ahead for genetic biocontainment. Nat. Commun. 15, 650 (2024).
Bansal, T. & Garg, S. Probiotics: from functional foods to pharmaceutical products. Curr. Pharm. Biotechnol. 9, 267–287 (2008).
Cheng, A. G. et al. Design, construction, and in vivo augmentation of a complex gut microbiome. Cell 185, 3617–3636.e19 (2022).
Furuichi, M. et al. Commensal consortia decolonize Enterobacteriaceae via ecological control. Nature 633, 878–886 (2024).
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
Huang, X. et al. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. Cell Host Microbe 31, 1930–1943.e4 (2023).
Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731–16736 (2008).
Bredon, M. et al. Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13, 2374954 (2024).
Wende, M. et al. Suppression of gut colonization by multidrug-resistant Escherichia coli clinical isolates through cooperative niche exclusion. Nat. Commun. 16, 5426 (2025).
Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103 (2019).
Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341 (2011).
Atarashi, K. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015).
Suez, J. et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181–186 (2014).
Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079–1094 (2015).
Bedu-Ferrari, C. et al. In-depth characterization of a selection of gut commensal bacteria reveals their functional capacities to metabolize dietary carbohydrates with prebiotic potential. mSystems 9, e0140123 (2024).
Wu, Z. et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study. Front. Cell. Infect. Microbiol. 12, 1089991 (2022).
Qin, X. et al. Gut microbiota predict retinopathy in patients with diabetes: a longitudinal cohort study. Appl. Microbiol. Biotechnol. 108, 497 (2024).
Hu, Y. et al. Causal relationship between gut microbiota and diabetic neuropathy: a Mendelian randomization and 16S rRNA sequencing analysis. Front. Endocrinol. 16, 1632406 (2025).
Xu, M. et al. Causal effects of gut microbiota on diabetic neuropathy: a two-sample Mendelian randomization study. Front. Endocrinol. 15, 1388927 (2024).
Zhang, L. et al. Alterations of the gut microbiota in patients with diabetic nephropathy. Microbiol. Spectr. 10, e0032422 (2022).
Kaye, D. M. et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation 141, 1393–1403 (2020).
Marques, F. Z. et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135, 964–977 (2017).
Chi, J. et al. Precision probiotics regulate blood glucose, cholesterol, body fat percentage, and weight under eight-week high-fat diet. Metabolites 15, 642 (2025).
Zhang, D. et al. Short-chain fatty acids in diseases. Cell Commun. Signal. 21, 212 (2023).
Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
Liang, J. Q. et al. A probiotic formula for modulation of colorectal cancer risk via reducing CRC-associated bacteria. Cells 12, 1244 (2023).
Chowdhury, S. et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med. 25, 1057–1063 (2019).
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293–305 (2019).
Ning, L. et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat. Commun. 14, 7135 (2023).
Govaert, M. et al. Survival of probiotic bacterial cells in the upper gastrointestinal tract and the effect of the surviving population on the colonic microbial community activity and composition. Nutrients 16, 2791 (2024).
Cao, F. et al. Engineering clinically relevant probiotics with switchable ‘nano-promoter’ and ‘nano-effector’ for precision tumor therapy. Adv. Mater. 36, e2304257 (2024).
Mainali, K., Bewick, S., Vecchio-Pagan, B., Karig, D. & Fagan, W. F. Detecting interaction networks in the human microbiome with conditional Granger causality. PLoS Comput. Biol. 15, e1007037 (2019).
Angermueller, C., Pärnamaa, T., Parts, L. & Stegle, O. Deep learning for computational biology. Mol. Syst. Biol. 12, 878 (2016).
Zhang, Y. et al. Screening antimicrobial peptides and probiotics using multiple deep learning and directed evolution strategies. Acta Pharm. Sin. B 14, 3476–3492 (2024).
Hanson, B. et al. Garbage in, garbage out: mitigating risks and maximizing benefits of AI in research. Nature 623, 28–31 (2023).
Wu, G. et al. A core microbiome signature as an indicator of health. Cell 187, 6550–6565.e11 (2024).
Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).
Passaro, S. et al. Boltz-2: towards accurate and efficient binding affinity prediction. Preprint at bioRxiv https://doi.org/10.1101/2025.06.14.659707 (2025).
Zhao, H. et al. Protein–peptide docking with a rational and accurate diffusion generative model. Nat. Mach. Intell. 7, 1308–1321 (2025).
Mooney, C., Haslam, N. J., Pollastri, G. & Shields, D. C. Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity. PLoS ONE 7, e45012 (2012).
Fernández-Díaz, R. et al. AutoPeptideML: a study on how to build more trustworthy peptide bioactivity predictors. Bioinformatics 40, btae555 (2024).
Du, Z., Ding, X., Xu, Y. & Li, Y. UniDL4BioPep: a universal deep learning architecture for binary classification in peptide bioactivity. Brief. Bioinform. 24, bbad135 (2023).
Pronk, S. et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845–854 (2013).
Dominguez, C., Boelens, R. & Bonvin, A. M. J. J. HADDOCK: a protein–protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125, 1731–1737 (2003).
Stark, H. et al. BoltzGen: toward universal binder design. Preprint at bioRxiv https://doi.org/10.1101/2025.11.20.689494 (2025).
Graber, D. et al. Resolving data bias improves generalization in binding affinity prediction. Nat. Mach. Intell. 7, 1713–1725 (2025).
Wu, L. et al. Data-driven prediction of colonization outcomes for complex microbial communities. Nat. Commun. 15, 2406 (2024).
Carr, A., Baliga, N. S., Diener, C. & Gibbons, S. M. Personalized Clostridioides difficile engraftment risk prediction and probiotic therapy assessment in the human gut. Cell Syst. 16, 101367 (2025).
Heinken, A. et al. Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine. Nat. Biotechnol. 41, 1320–1331 (2023).
Quinn-Bohmann, N. et al. Microbial community-scale metabolic modeling predicts personalized short chain fatty acid production profiles in the human gut. Preprint at bioRxiv https://doi.org/10.1101/2023.02.28.530516 (2023).
Silva-Andrade, C. et al. A machine-learning approach for predicting butyrate production by microbial consortia using metabolic network information. PeerJ 13, e19296 (2025).
Gutierrez, M. W. et al. Early-life gut mycobiome core species modulate metabolic health in mice. Nat. Commun. 16, 1467 (2025).
Pattaroni, C. et al. Early life inter-kingdom interactions shape the immunological environment of the airways. Microbiome 10, 34 (2022).
Aminian-Dehkordi, J., Parsa, M., Dickson, A. & Mofrad, M. R. K. SIMBA-GNN: mechanistic graph learning for microbiome prediction. npj Syst. Biol. Appl. 12, 8 (2025).
Huang, H. et al. The mycobiome as integral part of the gut microbiome: crucial role of symbiotic fungi in health and disease. Gut Microbes 16, 2440111 (2024).
Sulaimany, S., Farahmandi, K. & Mafakheri, A. Computational prediction of new therapeutic effects of probiotics. Sci. Rep. 14, 11932 (2024).
Matsubara, V. H., Wang, Y., Bandara, H. M. H. N., Mayer, M. P. A. & Samaranayake, L. P. Probiotic lactobacilli inhibit early stages of Candida albicans biofilm development by reducing their growth, cell adhesion, and filamentation. Appl. Microbiol. Biotechnol. 100, 6415–6426 (2016).
Thiele, I. et al. Personalized whole-body models integrate metabolism, physiology, and the gut microbiome. Mol. Syst. Biol. 16, e8982 (2020).
Quinn, R. A. et al. Niche partitioning of a pathogenic microbiome driven by chemical gradients. Sci. Adv. 4, eaau1908 (2018).
Mougi, A. pH adaptation stabilizes bacterial communities. npj Biodivers. 3, 32 (2024).
Harcombe, W. R. et al. Metabolic resource allocation in individual microbes determines ecosystem interactions and spatial dynamics. Cell Rep. 7, 1104–1115 (2014).
McCoubrey, L. E. et al. Active machine learning for formulation of precision probiotics. Int. J. Pharm. 616, 121568 (2022).
Cenikj, G. et al. From language models to large-scale food and biomedical knowledge graphs. Sci. Rep. 13, 7815 (2023).
Shin, E., Bhat, A. G. & Ramanathan, M. Large language models for clinical trial protocol assessments. Clin. Pharmacol. Ther. 119, 393–402 (2026).
Athaluri, S. A. et al. Exploring the boundaries of reality: investigating the phenomenon of artificial intelligence hallucination in scientific writing through ChatGPT references. Cureus 15, e37432 (2023).
Hatem, R., Simmons, B. & Thornton, J. E. A call to address AI ‘hallucinations’ and how healthcare professionals can mitigate their risks. Cureus 15, e44720 (2023).
Jiang, J. et al. Artificial intelligence in bioinformatics: a survey. Brief. Bioinform. 26, bbaf576 (2025).
Anh-Hoang, D., Tran, V. & Nguyen, L.-M. Survey and analysis of hallucinations in large language models: attribution to prompting strategies or model behavior. Front. Artif. Intell. 8, 1622292 (2025).
Lin, S., Hilton, J. & Evans, O. TruthfulQA: measuring how models mimic human falsehoods. In Proc. 60th Annu. Meet. Assoc. Comput. Linguist. 3266–3289 (ACL, 2022).
Zhao, Y. & Zhang, Y. HalluClean: a unified framework to combat hallucinations in LLMs. Proc. AAAI Conf. Artif. Intell. 40, 36092–36100 (2026).
Matsumoto, N. et al. KRAGEN: a knowledge graph-enhanced RAG framework for biomedical problem solving using large language models. Bioinformatics 40, btae353 (2024).
Gargari, O. K. & Habibi, G. Enhancing medical AI with retrieval-augmented generation: a mini narrative review. Digit. Health 11, 20552076251337177 (2025).
Pan, G., Chodnekar, V., Roy, A. & Wang, H. A cost–benefit analysis of on-premise large language model deployment: breaking even with commercial LLM services. Preprint at https://doi.org/10.48550/arXiv.2509.18101 (2025).
World Health Organization. Ethics and Governance of Artificial Intelligence for Health: Guidance on Large Multi-Modal Models (WHO, 2024).
Baliga, S., Muglikar, S. & Kale, R. Salivary pH: a diagnostic biomarker. J. Indian Soc. Periodontol. 17, 461–465 (2013).
Brinck, J. E. et al. Intestinal pH: a major driver of human gut microbiota composition and metabolism. Nat. Rev. Gastroenterol. Hepatol. 22, 639–656 (2025).
Lin, Y.-P., Chen, W.-C., Cheng, C.-M. & Shen, C.-J. Vaginal pH value for clinical diagnosis and treatment of common vaginitis. Diagnostics 11, 1996 (2021).
Brooks, S. G., Mahmoud, R. H., Lin, R. R., Fluhr, J. W. & Yosipovitch, G. The skin acid mantle: an update on skin pH. J. Invest. Dermatol. 145, 509–521 (2025).
Dickson, R. P. et al. Radiographic honeycombing and altered lung microbiota in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 200, 1544–1547 (2019).
Nicola, T. et al. A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation. Nat. Commun. 15, 7113 (2024).
Zawistowska-Rojek, A. et al. Evaluating the quality of selected commercial probiotic products, both dietary supplements and foods for special medical purposes. Foods 15, 373 (2026).
Drago, L., Rodighiero, V., Celeste, T., Rovetto, L. & De Vecchi, E. Microbiological evaluation of commercial probiotic products available in the USA in 2009. J. Chemother. 22, 373–377 (2010).
Vesa, T., Pochart, P. & Marteau, P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment. Pharmacol. Ther. 14, 823–828 (2000).
Cai, S. et al. Lactobacillus rhamnosus GG activation of dendritic cells and neutrophils depends on the dose and time of exposure. J. Immunol. Res. 2016, 7402760 (2016).
Weese, J. S. & Martin, H. Assessment of commercial probiotic bacterial contents and label accuracy. Can. Vet. J. 52, 43–46 (2011).
Oozeer, R. et al. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl. Environ. Microbiol. 72, 5615–5617 (2006).
Arioli, S., Koirala, R., Taverniti, V., Fiore, W. & Guglielmetti, S. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front. Microbiol. 9, 1720 (2018).
Goossens, D. et al. Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition. Dig. Liver Dis. 37, 44–50 (2005).
Wang, J., Zhang, J., Liu, W., Zhang, H. & Sun, Z. Metagenomic and metatranscriptomic profiling of Lactobacillus casei Zhang in the human gut. npj Biofilms Microbiomes 7, 55 (2021).
Basu, S., Paul, D. K., Ganguly, S., Chatterjee, M. & Chandra, P. K. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J. Clin. Gastroenterol. 43, 208–213 (2009).
Salamat, S., Jahan-Mihan, A., Gharibvand, L., Reza Tabandeh, M. & Mansoori, A. Multi-species synbiotic supplementation increased fecal short chain fatty acids and anti-inflammatory cytokine interleukin-10 in adult men with dyslipidemia; a randomized, double-blind, clinical trial. Cytokine 179, 156608 (2024).
Alander, M. et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 65, 351–354 (1999).
Goossens, D. et al. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment. Pharmacol. Ther. 18, 495–505 (2003).
Radicioni, M. et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur. J. Nutr. 58, 3161–3170 (2019).
Yin, X., Lee, B., Zaragoza, J. & Marco, M. L. Dietary perturbations alter the ecological significance of ingested Lactobacillus plantarum in the digestive tract. Sci. Rep. 7, 7267 (2017).
Maltby, R., Leatham-Jensen, M. P., Gibson, T., Cohen, P. S. & Conway, T. Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine. PLoS ONE 8, e53957 (2013).
Deriu, E. et al. Probiotic bacteria reduce Salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe 14, 26–37 (2013).
Jankowska, A., Laubitz, D., Antushevich, H., Zabielski, R. & Grzesiuk, E. Competition of Lactobacillus paracasei with Salmonella enterica for adhesion to Caco-2 cells. J. Biomed. Biotechnol. 2008, 357964 (2008).
Orlando, A., Linsalata, M., Notarnicola, M., Tutino, V. & Russo, F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol. 14, 19 (2014).
Guo, S. et al. Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function. J. Pediatr. Gastroenterol. Nutr. 64, 404–412 (2017).
Gao, J. et al. A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function. Front. Microbiol. 10, 477 (2019).
Prete, R. et al. Beneficial bile acid metabolism from Lactobacillus plantarum of food origin. Sci. Rep. 10, 1165 (2020).
Gui, L. et al. Lactobacillus rhamnosus GG maintains gut microbiota stability and promotes intestinal adaptation via activated intestinal farnesoid X receptor signaling in short bowel syndrome. Commun. Biol. 8, 816 (2025).
Yao, L. et al. A selective gut bacterial bile salt hydrolase alters host metabolism. eLife 7, e37182 (2018).
Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 (1999).
Boonma, P. et al. Probiotic VSL#3 treatment reduces colonic permeability and abdominal pain symptoms in patients with irritable bowel syndrome. Front. Pain Res. 2, 691689 (2021).
Ahlroos, T. & Tynkkynen, S. Quantitative strain-specific detection of Lactobacillus rhamnosus GG in human faecal samples by real-time PCR. J. Appl. Microbiol. 106, 506–514 (2009).
Sequeira, I. R., Lentle, R. G., Kruger, M. C. & Hurst, R. D. Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. PLoS ONE 9, e99256 (2014).
Adriaanse, M. P. M. et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment. Pharmacol. Ther. 37, 482–490 (2013).
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I. & Bjarnason, I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123, 450–460 (2002).
D’Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218–2224 (2012).
Borruel, N. et al. Increased mucosal tumour necrosis factor α production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 51, 659–664 (2002).
Zhou, S. et al. Probiotic treatment induces changes in intestinal microbiota but does not alter SCFA levels in peritoneal dialysis patients — a randomized, placebo-controlled trial. Sci. Rep. 14, 31413 (2024).
Gibson, G. R., Beatty, E. R., Wang, X. & Cummings, J. H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108, 975–982 (1995).
Kruse, H. P., Kleessen, B. & Blaut, M. Effects of inulin on faecal bifidobacteria in human subjects. Br. J. Nutr. 82, 375–382 (1999).
Anzawa, D. et al. Effects of synbiotics containing Bifidobacterium animalis subsp. lactis GCL2505 and inulin on intestinal bifidobacteria: a randomized, placebo-controlled, crossover study. Food Sci. Nutr. 7, 1828–1837 (2019).